Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Refining "Track And Trace" Standards For Rx Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is holding a two-day workshop on the next steps to take to secure the supply chain and protect consumers from counterfeit drugs; industry stakeholders discussing formation of consortium.

You may also be interested in...



Track and Trace Standards Coming Shortly, FDA Says

Standards were required in FDAAA; industry asked for them in part to avoid conflicts with California pedigree law that will be implemented in 2015.

FDA Delays Implementation Of Radiofrequency Identification Standards

With many new technologies to combat counterfeiting, agency appears to want more time to get the implementation of quality control legislation right, say some sources.

FDA Takes First Step Towards "Track And Trace" As Final Guidance Lengthens Identifiers For Drug Packaging

Agency had proposed an eight-digit system, but moved to 20 digits in final document after recommendation from PhRMA.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel